China’s plasma collection was 5,800 tons in 2015. The overall demand needed by the country is predicted to be at 12,000 tons. The blood products market in China is primarily driven by the geriatric populace in need of blood transfusions. Other factors include surgeries involving chronic diseases such as cancer.
A major factor thwarting progress of the market is the lack of blood centers. Red blood cells have a lifespan of 42 days, while platelets have 5 day lifetime. This factor could also be the panic related to 1980s when one of the blood samples provided was found to be HIV-positive. Since then blood drives are done more cautiously at colleges, healthcare centers, and donations. The market is expected to display growth over the forecast period (2018-2023).
Products encompassed in the market are human albumin, Tetanus immunoglobulin, Human rabies immunoglobulin, Human Immunoglobulin (pH4) for Intravenous Injection, Hepatitis B Immunoglobulin, Human Prothrombin Complex, Blood Coagulation Factor VIII, and human immunoglobulin.
Browse Full Report With TOC @ http://www.radiantinsights.com/research/blood-products-markets-in-china